Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$4.20
-$0.06(-1.43%)
At close: 4:00 PM EDT
$4.20
-$0.06(-1.43%)
Day’s Range― - ―
52-Week Range$1.80 - $31.50
Previous CloseN/A
Volume17.00K
Average Volume (3M)182.02K
Market Cap
$35.18M
Enterprise Value$28.67
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.63
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding16,832,014
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet OptionalityThe balance sheet shows debt-to-equity near zero in 2025, materially lowering interest and refinancing risk. Low leverage gives Enlivex structural financial flexibility to fund clinical milestones or strategic initiatives over multiple quarters without the fixed-cost burden of heavy debt, improving solvency prospects if financing access continues.
Regulatory Milestone: FDA RMAT DesignationThe RMAT designation creates an expedited regulatory pathway with earlier FDA engagement and potential accelerated development support. This structural regulatory validation can reduce development timeline risk and increase the probability of a viable regulatory strategy, improving long-term commercialization prospects for Allocetra in a large OA patient pool.
Large Disclosed Digital-asset TreasuryA roughly $1.1B RAIN token treasury provides a substantial non-operating asset base that can be deployed for R&D funding, debt repayment, or strategic investments. The size and disclosure of this treasury give Enlivex multi-quarter optionality to support clinical programs without immediate dilution from operating shortfalls, assuming liquidity and management access to proceeds.
Bears Say
Persistent Cash BurnOperating and free cash flow have been negative every reported year, indicating structural dependence on external funding to sustain operations and trials. Continued cash burn forces recurring capital raises or asset monetization, which can dilute shareholders and create execution risk if market access or treasury liquidity weakens over the next several quarters.
No Meaningful Operating RevenueEffectively zero revenue and persistent negative gross profit through 2025 show the business lacks commercial cash flows and operating leverage. Absent successful late-stage trials and approval, the company cannot rely on durable operating earnings, keeping long-term viability tethered to clinical outcomes rather than recurring product sales.
Concentration Risk From Crypto-linked FinancingMajor financing and capital-allocation plans are tied to RAIN tokens and a single institutional partner, concentrating balance-sheet exposure to one digital asset and counterpart. This structural reliance heightens market and regulatory risk, making funding availability and NAV stability contingent on crypto market liquidity and evolving regulation over months to years.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.80 and its highest was $31.50 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $35.18M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 264 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Overvalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 16,832,014 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.38%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
―
Insiders
0.18% Mutual Funds
― Other Institutional Investors
99.82% Public Companies and
Individual Investors